Stevens Capital Management LP Biomarin Pharmaceutical Inc Transaction History

Stevens Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$64.27 - $86.37 $1.2 Million - $1.62 Million	-18,738 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$67.4 - $85.11 $65,243 - $82,386	-968 Reduced 4.91%	18,738 $1.26 Million
Q2 2019 Jul 31, 2019	SELL	$80.35 - $93.9 $1.39 Million - $1.62 Million	-17,240 Reduced 46.66%	19,706 $1.69 Million
Q1 2019 May 03, 2019	BUY	$84.2 - $98.62 $3.11 Million - $3.64 Million	36,946 New	36,946 $3.28 Million
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $1.62 Million - $1.91 Million	-20,048 Closed	0 $0
Q3 2017 Nov 01, 2017	BUY	$80.6 - $94.95 $1.62 Million - $1.9 Million	20,048	20,048 $1.87 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Stevens Capital Management LP with notifications on news.